Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis

Tillett, William; Shaddick, Gavin; Jobling, Amelia; Askari, Ayman; Cooper, Annie; Creamer, Paul; Clunie, Gavin; Helliwell, Philip S.; James, Jana; Kay, Lesley; Korendowych, Eleanor; Lane, Suzanne; Packham, Jon; Shaban, Ragai; Thomas, Matthew L.; Williamson, Lyn; McHugh, Neil

doi:10.1093/rheumatology/kew433

Cited by 22 publications

(40 citation statements)

References 28 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNF inhibitors (TNFi) are also effective therapies for axSpA [28]. Studies reported signi cant improvements in work disability after commencement of TNFi therapy [29,30]. However, there was no correlation between TNFi used and loss of work ability in our study.…”

Section: Discussioncontrasting

confidence: 73%

Work Productivity is Associated With Disease Activity and Functional Ability in Chinese Patients With Axial Spondyloarthritis Using A Smart-Phone Management System: A Prospective Cohort Study

Wang¹,

Liu²,

Chen³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Axial spondyloarthritis usually affects young people and often leads to disability. We used the interactive mobile health tool to evaluate clinical characteristics and loss of work efficiency in China, and to analyze the association between the clinical characteristics and work disability in patients with axial spondyloarthritis.Methods: In total, 1187 patients with axial spondyloarthritis were included. Demographic properties, pharmacotherapy, disease activity, functionality and spinal mobility were studied and compared in both work disability and non- work disability patients. Logistic regressions were used to investigate the associations between the risk of work disability and clinical characteristics. The relationships between Work Productivity and Activity Impairment scores and clinical characteristics were assessed using Spearman correlation coefficients. Results: Of the participants, 60 or 5.05% were unemployed. The predictive factors for the occurrence of work disability were suffering from inflammatory bowel disease, higher Physician’s global assessment and higher Assessment of Spondyloarthritis International Society health index (ASASHI) scores (OR value was 3.35, 1.32 and 1.45 respectively). Absenteeism, presenteeism, overall work impairment and activity impairment in all employed patients were 10.40%, 23.53%, 30.57% and 25.35% respectively. Factors significantly associated with higher presenteeism, overall work impairment and activity impairment loss were Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, Ankylosing Spondylitis Disease Activity Score, ASASHI, nocturnal pain, total back pain, and Patient’s global assessment (r >0.5), while non-steroidal anti-inflammatory drugs treatment were significantly associated with a lower absenteeism loss. An increased ASDAS score was related to a decrease in work productivity.Conclusions: We used a Smart-Phone Management System to determine that axial spondyloarthritis had a significant influence on working conditions in China, and that the factors related to the disease had a significant correlation with the risk and severity of lost work productivity. SpAMS is found be a time- and cost-saving disease management tool which can help patients with AS independently manage their disease and provide valuable data to their clinicians.

show abstract

Section: Discussioncontrasting

confidence: 73%

Work Productivity is Associated With Disease Activity and Functional Ability in Chinese Patients With Axial Spondyloarthritis Using A Smart-Phone Management System: A Prospective Cohort Study

Wang¹,

Liu²,

Chen³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Nonrandomized studies can provide important data over longer time frames, in a more real-world setting that complements RCT data. Data from the British Society of Rheumatology Biologics Registry 14 , the Danish Biologics Registry 15 , and a 2-year UK multicenter study of work disability in PsA 16 each support the view that work disability is prevalent among patients with PsA and is improved with better disease control, particularly with bDMARD.…”

Section: Editorialmentioning

confidence: 94%

Work Disability and the Cost-effectiveness of Drugs to Treat Rheumatic Diseases — Time for a New Dialogue?

Tillett

Bojke

2018

J Rheumatol

Self Cite

View full text Add to dashboard Cite

“…6,7 In addition to work productivity impairment, RA, PsA, and AS are associated with sleep disturbances and diminished sleep quality, which in turn affect the patient's cognition, mood, and functional status and intensify physical fatigue. 5,[8][9][10][11][12][13] Treatment with tumor necrosis factor (TNF) inhibitors has been shown to improve work productivity measures in short-and long-term studies of patients with RA, PsA, and AS, [14][15][16][17][18][19] and several studies among patients with AS and RA have demonstrated that anti-TNF treatments improve various measures of sleep quality. [20][21][22][23][24][25] As it specifically pertains to the anti-TNF agent adalimumab, patients with early RA treated with adalimumab plus methotrexate have shown significantly greater improvement in work productivity measures after 26 weeks of treatment 26 and over a 2-year period compared with patients treated with methotrexate alone.…”

Section: Introductionmentioning

confidence: 99%

“…Treatment with tumor necrosis factor (TNF) inhibitors has been shown to improve work productivity measures in short- and long-term studies of patients with RA, PsA, and AS, 14 – 19 and several studies among patients with AS and RA have demonstrated that anti-TNF treatments improve various measures of sleep quality. 20 – 25 As it specifically pertains to the anti-TNF agent adalimumab, patients with early RA treated with adalimumab plus methotrexate have shown significantly greater improvement in work productivity measures after 26 weeks of treatment 26 and over a 2-year period compared with patients treated with methotrexate alone.…”

Section: Introductionmentioning

confidence: 99%

Real-world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Tektonidou

Katsifis

Georgountzos

et al. 2020

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Objective: Our aim was to evaluate the effect of adalimumab on work productivity measures, overall activity impairment, and sleep quality in patients with active moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) treated in routine care settings in Greece and determine factors associated with work impairment and sleep disturbance. Methods: Patients with active moderate to severe RA ( n = 184), PsA ( n = 166), and AS ( n = 150) were enrolled in this 24-month, prospective, observational study at 80 hospital outpatient clinics and private practices throughout Greece. Patients received adalimumab alone or in combination with standard antirheumatic therapies according to routine care. Work productivity and sleep were assessed through two patient-reported outcome measures: the Work Productivity and Activity Impairment–General Health questionnaire and the Medical Outcomes Study Sleep Scale (MOS-SS). Pearson correlation coefficients were estimated to assess the association of work impairment and sleep disturbances with disease activity scores. Results: In the overall population, adalimumab significantly lowered absenteeism [mean (95% confidence interval) reduction, 18.9% (13.3–24.5%); n = 100]; presenteeism [40.0% (33.8–46.3%); n = 98], overall work productivity impairment [46.8% (40.4–53.2%); n = 94], activity impairment [47.0% (44.3–49.6); n = 421], and the MOS-SS sleep problems index [31.6 (29.5–34.1); n = 421] after 24-month treatment ( p < 0.001). Significant improvements were also noted across the RA, PsA, and AS subpopulations ( p < 0.05). Improvements in overall work impairment and sleep disturbance positively correlated with improvements in disease activity measures. Conclusion: Adalimumab improves work productivity and sleep problems while lowering disease activity in patients with moderate to severe RA, PsA, and AS managed in real-world settings.

show abstract

Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis

Abstract: We report significant and clinically meaningful improvements in both work disability and clinical outcomes after commencement of anti-TNF therapy in a real-world setting. Improvements in all outcomes among those commencing csDMARDs were slower and of a smaller magnitude.

Cited by 22 publications

References 28 publications

Work Productivity is Associated With Disease Activity and Functional Ability in Chinese Patients With Axial Spondyloarthritis Using A Smart-Phone Management System: A Prospective Cohort Study

Work Productivity is Associated With Disease Activity and Functional Ability in Chinese Patients With Axial Spondyloarthritis Using A Smart-Phone Management System: A Prospective Cohort Study

Work Disability and the Cost-effectiveness of Drugs to Treat Rheumatic Diseases — Time for a New Dialogue?

Real-world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Contact Info

Product

Resources

About